A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs AT 101 (Primary)
- Indications Glioblastoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Jun 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.